J Korean Diabetes.  2022 Jun;23(2):113-127. 10.4093/jkd.2022.23.2.113.

Recent Advances in Anti-Obesity Drugs

• Son JW

• KMID: 2531495
• DOI: http://doi.org/10.4093/jkd.2022.23.2.113

Abstract

Obesity is a chronic, complex, and heterogeneous disease that is affected by genetic, developmental, biological, and environmental factors; thus, it is necessary to approach obesity with an integrated and comprehensive treatment strategy. Because it is difficult to achieve and maintain successful long-term weight loss through lifestyle modifications in most obese patients, a pharmacological approach to the treatment of obesity should be considered as adjuvant therapy. According to the Korean Society for the Study of Obesity guidelines, patients who fail to lose weight with comprehensive lifestyle modifications and who have a body mass index of ≥ 25 kg/m² are eligible for weight loss medication treatment. Four drugs (orlistat, naltrexone extended-release [ER]/bupropion ER, phentermine/topiramate controlled-release, and liraglutide) have been approved for long-term use (> 12 weeks) to promote weight loss in Korea. Here, I will discuss these currently available anti-obesity agents as well as upcoming anti-obesity agents including semaglutide, setmelanotide, and tirzepatide in terms of obesity management.

Keyword

Liraglutide; Naltrexone/bupropion extended-release; Obesity; Phentermine/topiramate extended-release; Semaglutide; Setmelanotide; Tirzepatide

Reference

1.World Health Organization. Obesity and overweight. Available from:. https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight. (updated 2021 Jun 9).

2.Nam GE., Kim YH., Han K., Jung JH., Rhee EJ., Lee WY. Obesity fact sheet in Korea, 2020: prevalence of obesity by obesity class from 2009 to 2018. J Obes Metab Syndr. 2021. 30:141–8.

3.Ward ZJ., Bleich SN., Cradock AL., Barrett JL., Giles CM., Flax C. Projected U.S. state-level prevalence of adult obesity and severe obesity. N Engl J Med. 2019. 381:2440–50.

4.Korean Society for the Study of Obesity. Quick reference guideline 2020. Seoul: Korean Society for the Study of Obesity;2020.

5.Korner J., Aronne LJ. The emerging science of body weight regulation and its impact on obesity treatment. J Clin Invest. 2003. 111:565–70.

6.Lowe MR. Self-regulation of energy intake in the pre-vention and treatment of obesity: is it feasible? Obes Res. 2003. 11(Suppl):44S–59S.

7.Foster G. The behavioral approach to treating obesity. Am Heart J. 2006. 151:625–7.

8.Apovian CM., Aronne LJ., Bessesen DH., McDonnell ME., Murad MH., Pagotto U. Pharmacological management of obesity: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2015. 100:342–62. Erratum in: J Clin Endocrinol Metab 2015, 100: 2135–6.

9.World Health Organization. Regional Office for the West-ern Pacific. The Asia-Pacific perspective: redefining Obesity and its treatment. Sydney: Health Communications Australia;2000.

10.Bray GA., Heisel WE., Afshin A., Jensen MD., Dietz WH., Long M. The science of obesity management: an endocrine society scientific statement. Endocr Rev. 2018. 39:79–132.

11.Sharretts J., Galescu O., Gomatam S., Andraca-Carrera E., Hampp C., Yanoff L. Cancer risk associated with lorcase-rin- the FDA's review of the CAMELLIA-TIMI 61 trial. N Engl J Med. 2020. 383:1000–2.

12.Nelson DL., Gehlert DR. Central nervous system biogenic amine targets for control of appetite and energy expenditure. Endocrine. 2006. 29:49–60.

13.Hirsch J., Mackintosh RM., Aronne LJ. The effects of drugs used to treat obesity on the autonomic nervous system. Obes Res. 2000. 8:227–33.

14.Wilding J., Van Gaal L., Rissanen A., Vercruysse F., Fitchet M. A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects. Int J Obes Relat Metab Dis-ord. 2004. 28:1399–410.

15.Verrotti A., Scaparrotta A., Agostinelli S., Di Pillo S., Chi-arelli F., Grosso S. Topiramate-induced weight loss: a review. Epilepsy Res. 2011. 95:189–99.

16.Allison DB., Gadde KM., Garvey WT., Peterson CA., Schwiers ML., Najarian T. Controlled-release phenter-mine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity (Silver Spring). 2012. 20:330–42.

17.Gadde KM., Allison DB., Ryan DH., Peterson CA., Troupin B., Schwiers ML. Effects of low-dose, controlled-re-lease, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet. 2011. 377:1341–52. Erratum in: Lancet 2011, 377: 1494.

18.Garvey WT., Ryan DH., Look M., Gadde KM., Allison DB., Peterson CA. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/ topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr. 2012. 95:297–308.

19.Khera R., Murad MH., Chandar AK., Dulai PS., Wang Z., Prokop LJ. Association of pharmacological treatments for obesity with weight loss and adverse events: a systematic review and meta-analysis. JAMA. 2016. 315:2424–34. Erratum in: JAMA 2016;316):995.

20.VIVUS LLC. QSYMIA® (phentermine and topiramate extended-release) capsules, for oral use. Available from:. https://qsymia.com/patient/include/media/pdf/pre-scribing-information.pdf?v=0422.

21.Mines D., Tennis P., Curkendall SM., Li DK., Peterson C., Andrews EB. Topiramate use in pregnancy and the birth prevalence of oral clefts. Pharmacoepidemiol Drug Saf. 2014. 23:1017–25.

22.Fujioka K. Safety and tolerability of medications approved for chronic weight management. Obesity (Silver Spring). 2015. 23(Suppl 1):S7–11.

23.Greenway FL., Whitehouse MJ., Guttadauria M., Ander-son JW., Atkinson RL., Fujioka K. Rational design of a combination medication for the treatment of obesity. Obesity (Silver Spring). 2009. 17:30–9.

24.Billes SK., Sinnayah P., Cowley MA. Naltrexone/bupropion for obesity: an investigational combination pharmaco-therapy for weight loss. Pharmacol Res. 2014. 84:1–11.

25.Greenway FL., Fujioka K., Plodkowski RA., Mudaliar S., Guttadauria M., Erickson J. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, pla-cebo-controlled, phase 3 trial. Lancet. 2010. 376:595–605. Erratum in: Lancet 2010;376:594. Erratum in: Lancet 2010;376:1392.

26.Apovian CM., Aronne L., Rubino D., Still C., Wyatt H., Burns C. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity (Silver Spring). 2013. 21:935–43.

27.Wadden TA., Foreyt JP., Foster GD., Hill JO., Klein S., O'Neil PM. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity (Silver Spring). 2011. 19:110–20.

28.Hollander P., Gupta AK., Plodkowski R., Greenway F., Bays H., Burns C. Effects of naltrexone sustained-release/ bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. Diabetes Care. 2013. 36:4022–9. Erratum in: Diabetes Care 2014;37:587.

29.Takeda Pharmaceuticals America. CONTRAVE (naltrexone HCl and bupropion HCl) ExtendedRelease Tablets. Available from:. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/200063s000lbl.pdf.

30.Nissen SE., Wolski KE., Prcela L., Wadden T., Buse JB., Bakris G. Effect of naltrexone-bupropion on major adverse cardiovascular events in overweight and obese patients with cardiovascular risk factors: a randomized clinical trial. JAMA. 2016. 315:990–1004.

31.Kelly AS., Auerbach P., Barrientos-Perez M., Gies I., Hale PM., Marcus C. A randomized, controlled trial of liraglutide for adolescents with obesity. N Engl J Med. 2020. 382:2117–28.

32.Secher A., Jelsing J., Baquero AF., Hecksher-S⊘rensen J., Cowley MA., Dalb⊘ge LS. The arcuate nucleus medi-ates GLP-1 receptor agonist liraglutide-dependent weight loss. J Clin Invest. 2014. 124:4473–88.

33.Kanoski SE., Hayes MR., Skibicka KP. GLP-1 and weight loss: unraveling the diverse neural circuitry. Am J Physiol Regul Integr Comp Physiol. 2016. 310:R885–95.

34.van Can J., Sloth B., Jensen CB., Flint A., Blaak EE., Saris WH. Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults. Int J Obes (Lond). 2014. 38:784–93.

35.Pi-Sunyer X., Astrup A., Fujioka K., Greenway F., Halpern A., Krempf M. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015. 373:11–22.

36.Davies MJ., Bergenstal R., Bode B., Kushner RF., Lewin A., Skj⊘th TV. Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial. JAMA. 2015. 314:687–99. Erratum in: JAMA 2016;315:90.

37.Wadden TA., Hollander P., Klein S., Niswender K., Woo V., Hale PM. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study. Int J Obes (Lond). 2013. 37:1443–51. Erratum in: Int J Obes (Lond) 2013;37:1514. Erratum in: Int J Obes (Lond) 2015;39:187.

38.le Roux CW., Astrup A., Fujioka K., Greenway F., Lau DCW., Van Gaal L. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Lancet. 2017. 389:1399–409. Erratum in: Lancet 2017;389:1398.

39.Blackman A., Foster GD., Zammit G., Rosenberg R., Aronne L., Wadden T. Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial. Int J Obes (Lond). 2016. 40:1310–9.

40.Marso SP., Daniels GH., Brown-Frandsen K., Kristensen P., Mann JF., Nauck MA. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016. 375:311–22.

41.Monami M., Nreu B., Scatena A., Cresci B., Andreozzi F., Sesti G. Safety issues with glucagon-like peptide-1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): data from randomized controlled trials. Diabetes Obes Metab. 2017. 19:1233–41.

42.Gallo M. Thyroid safety in patients treated with liraglutide. J Endocrinol Invest. 2013. 36:140–5.

43.Rhythm Pharmaceuticals. IMCIVREE (setmelanotide) injection, for subcutaneous use. Available from:. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213793s000lbl.pdf.

44.Ayers KL., Glicksberg BS., Garfield AS., Longerich S., White JA., Yang P. Melanocortin 4 receptor pathway dys-function in obesity: patient stratification aimed at MC4R agonist treatment. J Clin Endocrinol Metab. 2018. 103:2601–12.

45.Jeong JK., Kim JG., Lee BJ. Participation of the central melanocortin system in metabolic regulation and energy homeostasis. Cell Mol Life Sci. 2014. 71:3799–809.

46.Clément K., van den Akker E., Argente J., Bahm A., Chung WK., Connors H. Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials. Lancet Diabetes Endocrinol. 2020. 8:960–70.

47.Knudsen LB., Lau J. The discovery and development of liraglutide and semaglutide. Front Endocrinol (Lausanne). 2019. 10:155.

48.Wilding JPH., Batterham RL., Calanna S., Davies M., Van Gaal LF., Lingvay I. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021. 384:989–1002.

49.Davies M., Færch L., Jeppesen OK., Pakseresht A., Pedersen SD., Perreault L. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021. 397:971–84.

50.Wadden TA., Bailey TS., Billings LK., Davies M., Frias JP., Koroleva A. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial. JAMA. 2021. 325:1403–13.

51.Rubino D., Abrahamsson N., Davies M., Hesse D., Greenway FL., Jensen C. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 2021. 325:1414–25.

52.Kadowaki T., Isendahl J., Khalid U., Lee SY., Nishida T., Ogawa W. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, dou-ble-blind, double-dummy, placebo-controlled, phase 3a trial. Lancet Diabetes Endocrinol. 2022. 10:193–206.

53.Rubino DM., Greenway FL., Khalid U., O'Neil PM., Rosenstock J., S⊘rrig R. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial. JAMA. 2022. 327:138–50.

54.Marso SP., Holst AG., Vilsb⊘ll T. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2017. 376:891–2.

55.Novo Nordisk Inc. WEGOVY ^TM (semaglutide) injection 2.4mg. Available from:. https://www.novo-pi.com/we-govy.pdf.

56.Min T., Bain SC. The role of tirzepatide, dual GIP and GLP-1 receptor agonist, in the management of type 2 diabetes: the SURPASS clinical trials. Diabetes Ther. 2021. 12:143–57.

57.Rosenstock J., Wysham C., Frías JP., Kaneko S., Lee CJ., Fernández Landó L. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021. 398:143–55. Erratum in: Lancet 2021;398:212.

58.Frías JP., Davies MJ., Rosenstock J., Pérez Manghi FC., Fernández Landó L., Bergman BK. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021. 385:503–15.

59.Ludvik B., Giorgino F., Jódar E., Frias JP., Fernández Landó L., Brown K. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, paral-lel-group, phase 3 trial. Lancet. 2021. 398:583–98.

60.Garvey WT. New horizons. A new paradigm for treating to target with second-generation obesity medications. J Clin Endocrinol Metab. 2022. 107:e1339–47.